New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available

Vandana Abramson, Carlos L. Arteaga

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.

Original languageEnglish (US)
Pages (from-to)952-958
Number of pages7
JournalClinical Cancer Research
Volume17
Issue number5
DOIs
StatePublished - Mar 1 2011

Fingerprint

Drug Combinations
Breast Neoplasms
Natural History
Drug Resistance
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New strategies in HER2-overexpressing breast cancer : Many combinations of targeted drugs available. / Abramson, Vandana; Arteaga, Carlos L.

In: Clinical Cancer Research, Vol. 17, No. 5, 01.03.2011, p. 952-958.

Research output: Contribution to journalReview article

@article{29106760632b4c459f9861fcfcb5d97c,
title = "New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available",
abstract = "The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.",
author = "Vandana Abramson and Arteaga, {Carlos L.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1947",
language = "English (US)",
volume = "17",
pages = "952--958",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - New strategies in HER2-overexpressing breast cancer

T2 - Many combinations of targeted drugs available

AU - Abramson, Vandana

AU - Arteaga, Carlos L.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.

AB - The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79952264098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952264098&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1947

DO - 10.1158/1078-0432.CCR-09-1947

M3 - Review article

C2 - 21248299

AN - SCOPUS:79952264098

VL - 17

SP - 952

EP - 958

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -